Chemomab Therapeutics Ltd Stock Fundamentals
| CMMB Stock | USD 0.59 0.07 10.61% |
Chemomab Therapeutics Ltd fundamentals help investors to digest information that contributes to Chemomab Therapeutics' financial success or failures. It also enables traders to predict the movement of Chemomab Stock. The fundamental analysis module provides a way to measure Chemomab Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Chemomab Therapeutics stock.
At present, Chemomab Therapeutics' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 626.1 K, whereas Selling General Administrative is forecasted to decline to about 6.4 M. Chemomab | Select Account or Indicator |
Chemomab Therapeutics Ltd Company Shares Outstanding Analysis
Chemomab Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Chemomab Therapeutics Shares Outstanding | 14.2 M |
Most of Chemomab Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Chemomab Therapeutics Ltd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Chemomab Shares Outstanding Historical Pattern
Today, most investors in Chemomab Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Chemomab Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Chemomab Therapeutics shares outstanding as a starting point in their analysis.
Chemomab Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Chemomab Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Chemomab Therapeutics Ltd has 14.2 M of shares currently outstending. This is 92.13% lower than that of the Biotechnology sector and 86.71% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 97.52% higher than that of the company.
Chemomab Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Chemomab Therapeutics's current stock value. Our valuation model uses many indicators to compare Chemomab Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Chemomab Therapeutics competition to find correlations between indicators driving Chemomab Therapeutics's intrinsic value. More Info.Chemomab Therapeutics Ltd is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . At present, Chemomab Therapeutics' Return On Equity is projected to drop based on the last few years of reporting.Comparative valuation analysis is a catch-all model that can be used if you cannot value Chemomab Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Chemomab Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Chemomab Therapeutics' earnings, one of the primary drivers of an investment's value.Chemomab Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Chemomab Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Chemomab Therapeutics could also be used in its relative valuation, which is a method of valuing Chemomab Therapeutics by comparing valuation metrics of similar companies.Chemomab Therapeutics is currently under evaluation in shares outstanding category among related companies.
Chemomab Fundamentals
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.49 | ||||
| Current Valuation | 168.31 M | ||||
| Shares Outstanding | 14.2 M | ||||
| Shares Owned By Insiders | 14.99 % | ||||
| Shares Owned By Institutions | 24.96 % | ||||
| Number Of Shares Shorted | 221.87 K | ||||
| Price To Book | 0.64 X | ||||
| EBITDA | (25.33 M) | ||||
| Net Income | (24.16 M) | ||||
| Cash And Equivalents | 51.72 M | ||||
| Cash Per Share | 4.53 X | ||||
| Total Debt | 392 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.48 X | ||||
| Book Value Per Share | 1.20 X | ||||
| Cash Flow From Operations | (23.55 M) | ||||
| Short Ratio | 2.14 X | ||||
| Earnings Per Share | (2.06) X | ||||
| Target Price | 7.0 | ||||
| Beta | -0.044 | ||||
| Market Capitalization | 9.39 M | ||||
| Total Asset | 22.15 M | ||||
| Retained Earnings | (88.68 M) | ||||
| Working Capital | 16.06 M | ||||
| Net Asset | 22.15 M |
About Chemomab Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Chemomab Therapeutics Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chemomab Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chemomab Therapeutics Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 0.00 | 0.00 | |
| Cost Of Revenue | 66.8 K | 83.1 K | |
| Stock Based Compensation To Revenue | 0.00 | 0.00 | |
| Sales General And Administrative To Revenue | 0.00 | 0.00 | |
| Research And Ddevelopement To Revenue | 0.00 | 0.00 | |
| Capex To Revenue | 0.00 | 0.00 | |
| Revenue Per Share | 0.00 | 0.00 | |
| Ebit Per Revenue | 0.00 | 0.00 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Chemomab Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Chemomab Therapeutics' short interest history, or implied volatility extrapolated from Chemomab Therapeutics options trading.
Pair Trading with Chemomab Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chemomab Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chemomab Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Chemomab Stock
| 0.55 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Chemomab Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chemomab Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chemomab Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chemomab Therapeutics Ltd to buy it.
The correlation of Chemomab Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chemomab Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chemomab Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Chemomab Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Chemomab Therapeutics Piotroski F Score and Chemomab Therapeutics Altman Z Score analysis. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Chemomab Stock analysis
When running Chemomab Therapeutics' price analysis, check to measure Chemomab Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemomab Therapeutics is operating at the current time. Most of Chemomab Therapeutics' value examination focuses on studying past and present price action to predict the probability of Chemomab Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chemomab Therapeutics' price. Additionally, you may evaluate how the addition of Chemomab Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Chemomab Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. If investors know Chemomab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemomab Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.06) | Return On Assets (0.49) | Return On Equity (0.91) |
The market value of Chemomab Therapeutics is measured differently than its book value, which is the value of Chemomab that is recorded on the company's balance sheet. Investors also form their own opinion of Chemomab Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Chemomab Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemomab Therapeutics' market value can be influenced by many factors that don't directly affect Chemomab Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemomab Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemomab Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.